tiprankstipranks
Trending News
More News >
Inoviq Ltd (AU:IIQ)
:IIQ
Advertisement

Inoviq Ltd (IIQ) AI Stock Analysis

Compare
2 Followers

Top Page

AU:IIQ

Inoviq Ltd

(Sydney:IIQ)

Rating:45Neutral
Price Target:
AU$0.50
▲(35.14%Upside)
The overall stock score is weighed down by significant profitability challenges, as reflected in the negative profit margins and low valuation score due to a negative P/E ratio. Despite promising revenue growth and a strong balance sheet, technical indicators show bearish momentum, further impacting the score.

Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)

Inoviq Ltd Business Overview & Revenue Model

Company DescriptionInoviq Ltd (IIQ) is a biotechnology company specializing in the development and commercialization of innovative diagnostic and therapeutic solutions aimed at improving patient outcomes. The company operates primarily in the healthcare sector, with a focus on cancer diagnostics and early detection technologies. Inoviq's core products include diagnostic tests and devices designed to enhance the precision and accuracy of cancer detection, providing significant value to healthcare providers and patients.
How the Company Makes MoneyInoviq Ltd makes money through the sale of its diagnostic products and services. The company's primary revenue streams include direct sales of diagnostic tests to healthcare institutions and laboratories, as well as licensing agreements with other companies that utilize Inoviq's proprietary technologies. Additionally, Inoviq may generate revenue through research and development partnerships, grants, and collaborations with other entities in the biotechnology and healthcare sectors. These partnerships can lead to milestone payments and royalties based on the commercialization success of co-developed products.

Inoviq Ltd Financial Statement Overview

Summary
Inoviq Ltd shows promising revenue growth but faces significant profitability challenges, as evidenced by negative profit margins. The balance sheet is strong with low leverage, but declining assets and equity could pose future risks. The cash flow statement reflects improvements but still indicates cash flow difficulties, requiring careful management to ensure sustainability.
Income Statement
35
Negative
Inoviq Ltd has shown consistent revenue growth, with total revenue increasing from AUD 398,193 in 2023 to AUD 535,118 in 2024, marking a significant growth rate of 34.37%. However, the company is struggling with profitability, reflected in negative gross profit, EBIT, and net income margins. The net profit margin remains negative at -1224.84%, indicating significant operational challenges.
Balance Sheet
60
Neutral
The company's balance sheet is relatively stable with a strong equity position. The debt-to-equity ratio is low at 0.02, indicating minimal leverage. The equity ratio is robust at 92.04%, showcasing a solid foundation. However, the declining total assets and stockholders' equity over time suggest potential future liquidity challenges.
Cash Flow
45
Neutral
Inoviq Ltd has demonstrated an improvement in free cash flow, reducing the negative free cash flow from AUD -7,316,841 in 2023 to AUD -4,497,261 in 2024. The operating cash flow to net income ratio is negative, reflecting ongoing operational cash flow challenges. Despite a significant financing cash flow, the negative free cash flow indicates continued cash burn.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue535.12K398.19K276.75K1.27M535.10K
Gross Profit454.11K-1.04M220.30K-2.21M-150.00K
EBITDA-6.63M-9.32M-7.04M-6.05M-2.90M
Net Income-6.55M-8.97M-18.20M-11.15M-3.25M
Balance Sheet
Total Assets21.71M21.51M30.78M33.52M7.37M
Cash, Cash Equivalents and Short-Term Investments9.23M7.81M15.39M5.00M7.33M
Total Debt403.74K730.71K998.69K1.26M0.00
Total Liabilities1.72M1.89M2.49M4.46M899.12K
Stockholders Equity19.99M19.62M28.29M29.06M6.48M
Cash Flow
Free Cash Flow-4.50M-7.32M-6.47M-6.05M-2.54M
Operating Cash Flow-4.32M-7.02M-6.06M-5.26M-2.54M
Investing Cash Flow-174.34K-292.27K-411.90K2.64M0.00
Financing Cash Flow5.91M-267.98K16.87M286.48K2.31M

Inoviq Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.37
Price Trends
50DMA
0.40
Negative
100DMA
0.39
Negative
200DMA
0.43
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
45.91
Neutral
STOCH
9.09
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IIQ, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.40, and below the 200-day MA of 0.43, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.91 is Neutral, neither overbought nor oversold. The STOCH value of 9.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IIQ.

Inoviq Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
AU$53.89M-51.49%80.84%57.59%
50
Neutral
AU$2.62B3.37-57.47%2.40%36.37%14.48%
45
Neutral
AU$41.30M-39.07%26.07%0.85%
45
Neutral
AU$24.52M-104.23%-17.26%
45
Neutral
AU$78.36M-47.52%44.61%16.40%
41
Neutral
AU$16.26M-71.10%76.17%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:IIQ
Inoviq Ltd
0.37
-0.23
-38.33%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.06
-46.15%
AU:RHY
Rhythm Biosciences Ltd.
0.06
0.00
0.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.07
0.02
40.00%
AU:GSS
Genetic Signatures Ltd.
0.34
-0.43
-55.84%

Inoviq Ltd Corporate Events

INOVIQ Ltd to Showcase at Key Investor Events
Jul 28, 2025

INOVIQ Ltd announced its participation in upcoming investor events, including the MST Financial Small Cap Spotlight webinar on July 30, 2025, and the TechKnow Invest Roadshow in Melbourne on August 19, 2025. These events will provide a platform for INOVIQ to present its exosome diagnostic and therapeutic portfolio, potentially enhancing its visibility and engagement with investors, which could positively impact its market positioning and stakeholder relations.

INOVIQ Updates on Key Biotech Programs
Jul 14, 2025

INOVIQ Limited has released an investor briefing providing updates on its key programs, EXO-OC and CAR-exosomes. This announcement highlights the company’s ongoing efforts to enhance its position in the biotechnology sector by advancing its diagnostic and therapeutic solutions, which could have significant implications for stakeholders and the industry at large.

INOVIQ Ltd to Host Investor Briefing on Cancer Diagnostics and Therapeutics
Jul 9, 2025

INOVIQ Ltd announced an upcoming online Investor Briefing scheduled for July 14, 2025, to discuss their EXO-OC ovarian cancer test and CAR-exosome therapy. The briefing will cover recent results in early detection of ovarian cancer and updates on CAR-exosome therapy in breast and lung cancers, highlighting the company’s advancements in cancer diagnostics and therapeutics.

INOVIQ’s New Cancer Treatment Shows Promising Lab Results
Jun 23, 2025

INOVIQ Limited has announced that its new cancer treatment, CAR-NK-EVs, has demonstrated the ability to kill 88% of breast and lung cancer cells in laboratory tests. This advancement highlights the potential of INOVIQ’s exosome platform to offer a more efficient, safer, and potentially more effective alternative to traditional CAR-T therapies. The announcement underscores the company’s commitment to advancing cancer treatment options and may enhance its positioning within the biotechnology sector.

INOVIQ’s Breakthrough Cancer Treatment Shows 88% Efficacy in Lab Tests
Jun 17, 2025

INOVIQ Ltd has announced a significant breakthrough in its exosome therapeutic program, with lab tests showing that its new cancer treatment kills 88% of triple-negative breast cancer and lung cancer cells. This innovative treatment uses engineered immune cell particles, CAR-NK-EVs, which target and kill cancer cells more precisely. The treatment could potentially be faster, safer, and more effective than traditional therapies, offering an ‘off-the-shelf’ solution that could benefit many patients. The next step involves testing in animal models before progressing to human clinical trials, marking a promising advancement in cancer treatment options.

Inoviq Ltd Trading Suspension Lifted Amid ASX Compliance Enquiries
Jun 2, 2025

Inoviq Ltd has announced that the suspension of its securities trading will be lifted following the release of further disclosure related to a recent price query. The Australian Securities Exchange (ASX) is continuing its enquiries into Inoviq’s compliance with listing rules, which may impact the company’s market operations and investor confidence.

INOVIQ’s Breakthrough in Early Ovarian Cancer Screening
Jun 2, 2025

INOVIQ Limited has announced significant results from its EXO-OC™ ovarian cancer test, presented at the American Society of Clinical Oncology Annual Meeting. The test achieved 77% sensitivity and 99.6% specificity in detecting ovarian cancer across all stages, with no missed early-stage diagnoses. This breakthrough positions INOVIQ as a leader in exosome technology, addressing the critical unmet need for early detection of ovarian cancer. The company plans to further develop and commercialize the test, seeking regulatory approval and aiming to launch it as a Laboratory Developed Test in the US, potentially saving lives by enabling earlier diagnosis and intervention.

Inoviq Ltd Securities Suspended from ASX Quotation
May 28, 2025

Inoviq Ltd’s securities have been suspended from quotation on the ASX following a trading halt initiated on May 26, 2025. The suspension is due to the need for further disclosure regarding issues highlighted in the company’s price query response, and will remain until ASX confirms compliance with its Listing Rules.

INOVIQ Clarifies ASX Query and Highlights Upcoming ASCO Presentation
May 28, 2025

INOVIQ Limited responded to an ASX price query by clarifying that the recent abstract published by the American Society of Clinical Oncology (ASCO) does not contain new, price-sensitive information beyond what was previously disclosed. However, the company highlighted the upcoming ASCO Annual Meeting presentation as potentially price-sensitive, emphasizing its confidentiality due to an ongoing patent application process. The company is adhering to ASCO’s strict embargo policies to avoid reputational and commercial risks, and it is ensuring compliance with listing rules while protecting its intellectual property.

INOVIQ Ltd Requests Trading Halt Pending Key Announcement
May 26, 2025

INOVIQ Ltd has requested a trading halt on its securities pending an announcement related to an ASX Price Query response. The halt will remain in effect until the company releases the announcement or until normal trading resumes on 28 May 2025. This move is part of the company’s compliance with ASX listing rules and aims to ensure transparency and proper dissemination of information to stakeholders.

Inoviq Ltd Announces Cessation of Securities
May 1, 2025

Inoviq Ltd has announced the cessation of 166,667 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could influence investor perception regarding the company’s ability to meet certain conditions tied to its securities.

INOVIQ Advances Exosome Programs and Expands Global Reach
Apr 30, 2025

INOVIQ Limited has made significant advancements in its exosome programs, including expanding its customer base for the EXO-NET technology across Europe, the US, and Asia, and developing AI-enhanced algorithms for early ovarian cancer detection. The company has also engaged the Peter MacCallum Cancer Centre to validate its CAR-exosome therapy for triple-negative breast cancer and published diagnostic performance results for its neuCA15-3 test. Additionally, INOVIQ has established a Medical and Scientific Advisory Board and appointed Dr. Emma Ball as Chief Commercial Officer. These developments are expected to enhance INOVIQ’s industry positioning and offer new therapeutic options for cancer patients.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025